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Powers), webalch@scripps.edu (W.E. Balch).Protein function is regulated by the proteostasis network (PN) [Balch, W.E., Morimoto, R.I., Dillin, A.
and Kelly, J.W. (2008) Adapting proteostasis for disease intervention. Science 319, 916–919], an inte-
gratedbiological system that generates andprotects the protein fold. The compositionof thePN is reg-
ulated by signaling pathways including the unfoldedprotein response (UPR), the heat-shock response
(HSR), the ubiquitin proteasome system (UPS) and epigenetic programs. Mismanagement of protein
folding and function during membrane trafﬁcking through the exocytic and endocytic pathways of
eukaryotic cells by the PN is responsible for a wide range of diseases that include, among others, lyso-
somal storage diseases, myelination diseases, cystic ﬁbrosis, systemic amyloidoses such as light chain
myeloma, andneurodegenerative diseases includingAlzheimer’s. Toxicity frommisfolding canbe cell
autonomous (affect the producing cell) or cell non-autonomous (affect a non-producing cell) or both,
and have either a loss-of-function or gain-of-toxic function phenotype. Herein, we review the role of
thePNand its regulatory transcriptional circuitry likely tobeoperational inmanaging theprotein fold
and function during membrane trafﬁcking. We emphasize the enabling principle of a ‘proteostasis
boundary (PB)’ [Powers, E.T., Morimoto, R.T., Dillin, A., Kelly, J.W., and Balch, W.E. (2009) Biochemical
and chemical approaches to diseases of proteostasis deﬁciency. Annu. Rev. Biochem. 78, 959–991]. The
PB is deﬁned by the combined effects of the kinetics and thermodynamics of folding and the kinetics
of misfolding, which are linked to the variable and adjustable PN capacity found different cell types.
Differences in the PN account for the versatility of protein folding and function in health, and the cel-
lular and tissue response to mutation and environmental challenges in disease. We discuss how
manipulation of the folding energetics or the PB throughmetabolites and pharmacological interven-
tion provides multiple routes for restoration of biological function in trafﬁcking disease.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction many different crowded environments deﬁned by the cell’s com-All organisms are locked into a limited set of protein folds from
which function must be achieved. The chemical and energetic
properties of the amino acid sequence of each polypeptide (the pri-
mary structure) dictated by the genome (DNA) and copied by RNA
for the purposes of translation, provides only a basic ‘score’ that
biology can read and interpret in multiple ways to evolve function-
ality through the activity of proteins. An understanding of how
cells manage an initially unfolded ensemble of polypeptides, and
generate and maintain the fold for function in human health re-
mains to be understood. This is because, unlike folding in a dilute
solution in the test tube, a protein in the eukaryotic cell is folded inchemical Societies. Published by E
ute for Chemical Biology, The
States.
), epowers@scripps.edu (E.T.partmentalized organization that includes the cytosol, mitochon-
dria, nucleus and the organelles comprising the exocytic and
endocytic pathways. It is now essential to understand how the bio-
logical folding pathways within each of these compartments inter-
pret the energetics of the protein fold and how it ultimately
inﬂuences protein activity(s) to direct organismal health.
To generate a natively folded protein, a cell uses a large number
of assistants to inﬂuence the acquisition, retention or removal of
the fold. These assistants strongly inﬂuence trafﬁcking through
the exocytic (endoplasmic reticulum (ER), Golgi, cell surface) and
endocytic pathways (cell surface, endosomes, lysosomes) that un-
iquely deﬁne the different eukaryotic cell and tissue biologies.
These biological assistants regulate the protein fold and function.
They comprise thousands of components that make up the protein
homeostasis, or ‘‘proteostasis”, network (PN) [1] and include well-
established signaling pathways such as the unfolded protein re-
sponse (UPR) [2–4], the heat-shock response (HSR) [5,6] andlsevier B.V. All rights reserved.
2640 D.M. Hutt et al. / FEBS Letters 583 (2009) 2639–2646Ca2+-sensing [7,8] and inﬂammatory pathways [9,10], collectively
referred to herein as the folding response system (FRS). The FRS
is complemented by the components of the ubiquitin-proteasome
system (UPS) found in the cytosol, and lysosomal and autophagic
degradation pathways collectively referred to as the degradation
response system (DRS) [1]. The FRS and DRS operate as an inte-
grated system to control the composition and capacity of variable
folding environments in different cell-types. Both are highly
responsive to physiological stress and changes in the metabolite
load (the metabolome) that is strongly inﬂuenced by diet [11–
13]. The PN is necessarily ancient and co-evolved with the remark-
able diversity of polypeptide sequences and folds, very likely play-
ing an instrumental role in expanding the capacity of polypeptides
to function in complex cell and tissue environments, and to per-
form increasingly precise cellular tasks associated with both cyto-
solic and membrane compartments found in eukaryotes.
Alterations in the polypeptide chain sequence (e.g., a mutation,
co- and post-translational modiﬁcations), or as a consequence of
a change in the concentration or the composition of the compo-
nents of the PN, leads to a breakdown in the network resulting in
human pathologies [14–16].
Herein, we focus on emerging evidence that a highly adaptive
PN in each cell type can sense and respond to both normal physi-
ology and a multiplicity of challenges to the protein fold for mobi-
lization of protein cargo through the exocytic endomembrane
trafﬁcking pathway. We ﬁrst describe a recently proposed global
mechanism for how the PN may interpret and inﬂuence protein
folding energetics to control the efﬁciency of folding based on
the concept of a minimal ‘proteostasis boundary’ or ‘PB’ [17]. The
PB is deﬁned by the combined effects of the kinetics and thermo-
dynamics of folding, and the kinetics of misfolding at a deﬁned
PN capacity of a particular cell type. Using the PB model as a frame-
work, we explore what may go wrong in misfolding diseases, and
discuss general dietary and pharmacological strategies that may
be used to enhance proteome function to protect us from disease.
2. The proteostasis network
While small, single domain proteins can fold efﬁciently in the
test tube, large, multi-domain proteins in the crowded environ-
ment of a cell often cannot. This circumstance dictates the need
for the PN [1]. As noted above, the PN is an integrated biological
system consisting of general and specialized chaperones, folding
enzymes, degradation components, and regulatory pathways that
control composition and concentration of the network components
[5,18]. The proteostasis program is constantly challenged by
changes in ATP, amino acid, and metabolite concentrations, ion
balance, and physical insults including among others, temperature
stress and pathogens. These not only alter the inherited capacity of
the proteostasis program, but are sensed by the FRS and the DRS,
which can either resolve the problem or promote cell death in
the case of severe pathology [19–22]. The PN is controlled both cell
autonomously and cell non-autonomously, the latter involving
both neuronal and non-neuronal signaling pathways [23,24]. Thus,
through transcriptional and post-translational mechanisms these
pathways continuously monitor and balance the folding and func-
tion capacity by reducing protein synthesis, by enhancing folding
and repair processes, and/or by mediating degradation.
While a core of PN components are highly conserved through-
out evolution [23], the composition and capacity of the network
is unique to each cell type [5]. Thus, any effort to understand
in vivo protein folding will require consideration of the interdepen-
dence of folding energetics and the PN within a given cell type, and
its response to the local tissue environment and organismal phys-
iology [25,26].3. Protein folding and energetics in biology and membrane
trafﬁc
An understanding of biological folding in the exocytic pathway
necessarily involves integrating the energetics of protein folding
with PN components. We have previously employed modeling to
address this conceptual challenge [27,28]. Referred to as the FoldEx
model [28], we described how the inherent energetics of the poly-
peptide chain are interpreted and inﬂuenced by the PN of the ER,
the ﬁrst step in a series of compartments required for the delivery
of protein cargo to a multitude of post-ER exocytic and endocytic
compartments, the cell surface, and the extracellular space. Using
the Michaelis–Menten approximation to describe the kinetics of
the PN components [28], we suggested that folding energetics
and the capacity of individual pathways of the PN involving trans-
lation, chaperoning, degradation, and export together determine
whether a given protein will fold and be exported from the ER,
or be targeted for degradation (Fig. 1A).
More recently, the concepts embodied in the FoldEx model
were extended to cover all situations where folding energetics
and the PN work together to achieve and maintain biological func-
tion. Referred to as FoldFx [17], the role of the translation machin-
ery, chaperones, and degradation pathways were more generally
related to acquisition of ‘function’, an event that is analogous to
the export step of the FoldEx model [28] (Fig. 1A). Like FoldEx,
the FRS and DRS that regulate the composition and levels of prote-
ostasis components are accommodated in the model by the adjust-
able concentrations of the PN components [17,28].
To appreciate the combined role of energetics and the PN in
folding of all compartments of the cell we have proposed the con-
cept of the PB [17] (Fig. 1B). The PB deﬁnes the minimal energetics
that a protein must have to achieve folding and function in the
context of a given PN capacity. The proteostasis boundary is best
illustrated as a surface in a three-dimensional space deﬁned by
protein folding thermodynamics (from unstable to stable), folding
kinetics (from slow to fast) and misfolding kinetics (from slow to
fast) (Fig. 1B). Here, the variable disposition and shape of the PB
is directly linked to the concentration of the proteostasis compo-
nents and the metabolome of the cell. We display interacting pro-
teins as a ‘biological network’ deﬁned by nodes (the proteins) and
edges (their links to other proteins within the network) (Fig. 1B).
Nodes are positioned according to their corresponding protein’s
folding energetics (their stabilities, folding rates, and misfolding
rates). In a healthy cell, the position of each node and its edges rel-
ative to the PB indicates its relative stability in a given cell type
reﬂecting the properties of the PN. Intriguingly, evidence suggests
that the PN does not possess excess capacity, likely because main-
taining capacity that is not immediately needed is a waste of cellu-
lar resources. Instead, the capacity of the PN may be adjusted to
provide just enough capacity for the folding load in a given cell
type at a given time [5,29,30]. We have suggested that by setting
the proteostasis boundary as a threshold for folding and mainte-
nance of the proteome [1], the network becomes sensitive to the
local metabolome and can be adjusted in response to pathology
to minimize damage and restore function. Thus, the PB can be
thought of as a rheostat that can be turned up or down to adjust
the folding capacity of a given cell type, ultimately achieving a le-
vel of functionality that dynamically drives human physiology and
protects us from disease.
4. Folded versus unfolded in the eyes of the PB
Given the above, when is a protein folded or misfolded from an
operational perspective? This is a challenging question, as up to
30% of proteins are now thought to have some level of intrinsic dis-
Fig. 1. The FoldEx and FoldFx models deﬁning the proteostasis boundary. (A) Illustrated are the interactive pathways that require the FRS to either complete the fold for
export from the ER (FoldEx model) [28] or for function (FoldFx model) [17], or contribute to misfolding, aggregation and degradation through the DRS. (B and C) Illustrated is
the proteostasis boundary (PB) (indicated by the arrow) deﬁned by kinetics of folding, kinetics of misfolding and thermodynamics reﬂecting a typical cellular composition of
the PN (see [28] for details). The location of a hypothetical cellular network facilitating cell function is indicated by the green nodes and edges, which, in a healthy cell (B) is
protected by the PN and therefore beneath the PB. In disease (C), a mutation can result in misfolding (red node and edge) leading to a loss-of-function disease, or aggregation
(black node) that can lead to a gain-of-toxic function disease. See [17,28] for a thorough treatment of the impact of mutation on the PN leading to human diseases. Panels B
and C are reproduced in a modiﬁed form from the Annual Review of Biochemistry, volume 78 [17] copyright 2009 by Annual Reviews, www.annualreviews.org.
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then redeﬁned by the PN in a fashion that tremendously extends
the initial role of the primary sequence encoded by the genome
in a particular cell type. Moreover, how does the local environ-
ment, a mutation, or co- or post-translational modiﬁcation alter a
protein’s ability to function in a biological network limited by
the PB? In the case of mutation, we have suggested that a change
in the amino acid sequence of a protein can signiﬁcantly alter its
folding energetics and its position relative to the inherited PB. As
a consequence, this could place the protein outside the PB where
it would become susceptible to substantial misfolding, aggrega-
tion, and/or degradation (Fig. 1C). The effect could be compounded
if, for example, the protein was involved in interactions that stabi-
lized other proteins resulting in ejection of multiple proteins from
the protective embrace of the PB. In contrast, changes in the PN in
disease, in response to diet and/or during aging could have a more
global effect on the folding of the proteome, particularly the loss of
core PN components such as heat-shock chaperones. Indeed, the
insulin growth factor 1 receptor (IGF1-R), which regulates the
expression of these components through heat-shock factor 1
(HSF-1), is now a well-recognized pathway that can be used to pro-
tect the cell against misfolding disease and prolong organismal
longevity [5].
5. The proteostasis boundary in trafﬁcking disease
Numerous diseases are a consequence of deﬁciencies in trafﬁck-
ing through the exocytic pathway and, in a number of cases, the
function and stability of proteins in the endocytic pathway. The
existence of compartmentalized function within the cell suggests
that the cell actually operates in the context of multiple PBs that
are unique for each compartment (Fig. 2). These compartments,particularly the ER and the Golgi, appear to be specialized to not
only generate the fold (the ER), but also to post-translationally
modify the fold (the Golgi) for downstream function in the cell, tis-
sue and organismal environments. Indeed, the PB deﬁned by the
highly specialized ER proteostasis program (PB* in Fig. 2) is likely
a ‘master regulator’ of folding for a given cell type given its rich
chaperone content, its capacity to generate disulﬁde bonds [2,31]
and its unique ability to add glycans that help stabilize the fold
[32], although the underlying basis for its organization remains ob-
scure. PB* clearly plays a primary role in deﬁning not only the basic
folding energetics during translation, but dictates both tissue and
organismal physiology through generation of cell surface receptors
and secreted proteins that communicate with other cells. While
not fully understood at this juncture, the operation of the PN and
conﬁguration of the PB in a given compartment is intimately linked
to the operation of the trafﬁcking components (vesicle budding
and fusion factors) that dictate the dynamics of exocytic and endo-
cytic compartment function and PN composition [33].
Proteins housed in endomembrane compartments face different
challenges. Soluble proteins that are temporarily or permanently
found in the lumen of compartments are necessarily subject to that
compartment’s local PN (Fig. 2). On the other hand, transmem-
brane proteins are subject to multiple folding challenges-lumenal
domains are subject to the PN of the local compartment. The cyto-
solic domain, although bathed in a ‘constant’ cytosolic environ-
ment, could be sensitive to PN components that are differentially
tethered to the membranes of the different compartments in which
they reside during their normal trafﬁcking itinerary. The lumenal
and cytosolic PNs must communicate with each other through un-
known mechanisms. Moreover, cells generate protein cargo that
must necessarily remain folded and function in the extracellular
environment (Fig. 2). This suggests that unique PNs and PBs deﬁne
Fig. 2. Compartmentalization and proteostasis boundaries. Illustrated is a hypothetical view of the differing organizations of the PB found in the indicated compartments. The
differences in the shape of the PBs reﬂect the differences in the PN present in each of these compartments or in the extracellular space that promotes folding and/or
maintenance of the fold.
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surrounding each cell type in a given tissue and the functional
composition of the blood plasma. Thus, as a consequence of com-
partmentalization in cellular physiology deﬁned by the endomem-
brane systems, both local and distal PBs will have a major impact
on protein function.
There are some features of the variant sequence (mutation) that
are common to all membrane trafﬁcking diseases that challenge
the PN and hence the PB controlling normal cell, tissue, and organ-
ismal function. First, a missense or nonsense mutation can destabi-
lize a protein, slow its folding, or accelerate its misfolding, such
that the protein’s folding energetics are no longer embraced by
the PB (Fig. 1C). Such mutations can have different phenotypes.
For example, mutations can trigger misfolding and degradation/
aggregation in the ER. Alternatively, they may allow normal traf-
ﬁcking to the cell surface but rapid targeting for degradation by
the lysosome through the endocytic pathway. Finally, they could
result in a ‘loss-of-function’ (e.g., mutation of an active site residue
in the case of enzymes), yet have normal ‘residency’ within the
exocytic and endocytic compartments in the cell if the overall fold
is not compromised. Second, trafﬁcking diseases can place a wide
range of demands on the PN. For example, expression levels can
have a major impact on the PN by saturating folding and function
capacity and/or lead to an imbalance of composition of multi-sub-
unit complexes, triggering a more general disruption that chal-
lenges the capacity of the PN to maintain the PB at a given set-
point. Thus, in considering the impact of protein folding energetics
on the PB and human physiology, it becomes necessary to appreci-
ate the fundamental basis for the folding problem in the context of
the PN and multiple PBs deﬁned by folding energetics that ulti-
mately dictate function.
6. Taking care of business – membrane trafﬁc and challenges to
the PN
Unlike the cytosol, the nucleus or the mitochondrion, which
have a ‘captive’ protein audience, the exocytic and endocytic path-
ways generate proteins for both local needs of the cell, and down-
stream needs reﬂecting tissue and/or organismal physiology. Thereare a minimum of four ways in which a misfolded protein in mem-
brane trafﬁcking pathways can be handled by the cell, tissue or
organism that are discussed below.
The ﬁrst possibility is that the variant is made, but is rapidly de-
graded because its energetics are outside the local PB in a particu-
lar cell type, leading to a loss-of-function phenotype. If the protein
is essential for the producing cell, losing it would be detrimental to
the cell, triggering death. We refer to this disease phenotype as cell
autonomous toxicity (CAT). On the other hand, if the degraded pro-
tein is required at a site that is distal and largely independent of
the producing cell’s function, we to this refer to cell non-autono-
mous toxicity (CNAT). While many secreted proteins traversing
the secretory pathway of, for instance, the liver or pancreas, are
likely to fall in the CNAT category, transmembrane proteins are
most likely to fall into CAT category as they are necessarily re-
tained by the producing cell and often essential for growth, prolif-
eration or function.
The second possibility is that the misfolded protein (either
transmembrane or soluble) accumulates in the producing cell
(e.g., it cannot be removed by the DRS). In this case, the accumu-
lated/aggregated protein sets off a cascade of cellular responses
to resolve the problem through FRS or DRS sensors that modulate
the PN, resulting in a new protective PB. While this class leads to
CAT unless resolved for both secreted and transmembrane pro-
teins, it could also contribute to CNAT if, for instance, the aggre-
gated protein trapped in the cell is not supplied at adequate
levels at distal sites to perform a required function.
The third possibility is that the accumulated/aggregated protein
(again, either secreted or transmembrane) exceeds the capacity of
the FRS/DRS to mitigate the problem and therefore triggers CAT
and cell death. This could also result in CNAT perturbation of both
tissue and host function.
Finally, there is a pervasive class of disease in which the de-
mand for production of even the wild-type protein exceeds the
capacity of PN, chronically activating FRS and, where unsatisﬁed,
cell death [3,10,34]. Because high expression can occur frequently
during development, it remains possible that many developmental
defects fall into this category and reﬂect the need for a specialized
PN for each cell type during periods of rapid growth and differen-
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known to be sensitive to the PN [35,36]. In any event, it is the pro-
ducing cell where the problem must be resolved. This may require
adjustment of both the PN composition and hence the PB to protect
the cell. Given the many mutations and polymorphisms that are
found in a wide range of proteins, and their largely unknown im-
pacts on the kinetics and/or thermodynamics of folding, it is not
surprising that different mutations even within a single protein
may trigger each of the distinct cellular responses indicated above.
Below we provide select examples of different classes of traf-
ﬁcking (mis)folding diseases and discuss their impact on the PN
and the PB. In each case, we emphasize emerging approaches that
could be used to augment the PN and its closely linked PB biology
that could contribute to restoration of function.
7. Treating transmembrane trafﬁcking disease
Cystic ﬁbrosis (CF) is an inherited disease caused by mutations
affecting the function of the cystic ﬁbrosis transmembrane conduc-
tance regulator (CFTR), a chloride/bicarbonate channel that regu-
lates the hydration of the ductwork found in multiple tissues
including the gall bladder, pancreas and intestine, and the surface
of the lung [37]. To date >1500 disease causing mutations have
been identiﬁed in the CFTR gene, suggesting that nearly every ami-
no acid in the protein is important at some level. As might be ex-
pected, clinical presentation of these different mutations is very
diverse, from mild to severe disease, reﬂecting the PN of the cell
type in which it is expressed, the location of the mutation, and
its impact on trafﬁcking and function dictated by the compartment
speciﬁc PB in the patient.
The most common mutation in CF disease is the Phe508 dele-
tion (DF508 CFTR). This mutation disrupts folding and targets the
protein for efﬁcient degradation by the DRS in the ER, thus theFig. 3. Effect of the PB on stability of CFTR during folding and trafﬁcking to the cell surf
through the exocytic pathway. Wild-type CFTR folds efﬁciently (indicated by the green)
contrast, theDF508 mutant is unstable in the ER (indicated by the red) and is efﬁciently d
a proteostasis regulator may correct the folding problem in the ER and restore delivery to
level of channel function (light green). The G551E mutant normally folds efﬁciently in the
requiring either a potentiator (to activate the channel directly), or a proteostasis regulat
hence, function.energetic destabilization contributed by losing Phe 508 exceeds
the folding capacity of the PB (Fig. 3). This conclusion is directly
supported by the observation of a signiﬁcant decrease in folding
kinetics and thermodynamic stability of the mutant fold when
compared to the wild-type CFTR [38]. Moreover, we have found
that the activity of the PN components that contribute to the
Hsp90 FRS system can either accelerate degradation, or protect
either mutant or wild-type CFTR from the DRS depending on their
levels in the cell [39]. Curiously, while stability in the ER can be im-
proved by blocking the DRS [40], it does not necessarily result in
export from the ER, suggesting that these events are uncoupled
and respond to different features of the fold and the local PN.
Not only does the DF508 phenotype fail to trigger known FRSs to
facilitate ‘correction’, DF508 expression does not appear to inter-
fere with cell proliferation or kill cells harboring the mutation (or
lacking the protein in the case of the null). These results suggest
that CF is best described as a CNAT disease. Indeed, it is the loss
of tissue function that is pathological. This is strongly reﬂected in
its coupling to sodium channel function, which together control
cell surface hydration of multiple tissues [41].
Achieving correction in CF disease is a multi-faceted problem.
First, we need to learn why the DF508-CFTR fold is unacceptable
to the PN and PB found in the ER of most cell types, and determine
if adjustments can be made pharmacologically that favor stability
(Fig. 3). This could be accomplished by small molecules referred
to as pharmacologic chaperones or ‘correctors’ [42], which directly
bind to the misfolding-prone protein and provide additional stabil-
ity as has been shown for G-protein coupled receptors (GPCRs)
[43], Gaucher’s [44,45] and transthyretin (TTR) mutants [46,47].
However, it is unlikely that simple pharmacologic correction of
ER export is sufﬁcient to solve the problem, given that the PN,
and hence the PB controlling stability and function at the surface,
is likely different from that of the ER. For example, the G551Eace. Illustrated is the effect of two CFTR variants (DF508 and G551E) on trafﬁcking
and is delivered to the cell surface where it has normal channel function (green). In
egraded by the DRS. Addition of corrector or alteration of the folding environment by
the cell surface where, given the proper environment, it may achieve a more normal
ER (like WT) (green) and trafﬁcs to the cell surface, but has a defective channel (red)
or that could affect the activity of the PN to improve open channel probability and
2644 D.M. Hutt et al. / FEBS Letters 583 (2009) 2639–2646mutation in CFTR has normal transport to the surface – yet lacks
channel function leading to disease (Fig. 3). Here, a pharmacologi-
cal chaperone referred to as a potentiator such as Vertex 770
(http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/) could
favorably alter (stabilize?) channel open probability, which is al-
tered in DF508 [37], therefore artiﬁcially imposing functionality,
as do agonists and antagonists for GPCRs [48]. Alternatively, cor-
rection could be achieved using proteostasis regulators [1], mole-
cules that adjust the composition and/or concentration of the PN
and hence the PB. The utility of proteostasis regulators in CF is sup-
ported by recent observations that correction can be achieved by
adjusting the activity of Hsp90-dependent folding steps in the ER
[39]. Moreover, a proteostasis regulator that adjusted the PB lead-
ing to folding and trafﬁcking of the protein from the ER, could, in
principle, provide a more stabilizing environment for function at
the cell surface if the proteostasis regulator modiﬁed the kinase
activities that regulate channel gating [37]. Of course, it is also pos-
sible that a combination of the various classes of pharmacologics
(correctors, potentiators and proteostasis regulators) may syner-
gize as has been observed for Gaucher’s disease where rapid degra-
dation could be reduced by proteostasis regulator, allowing
sufﬁcient protein to be produced to engage a corrector [45].
Although the above approaches may provide beneﬁt, they beg
the question of the real problem in CF disease and CNAT tissue dys-
function. It now may be important to deﬁne the signaling path-
ways that normally regulate surface hydration and thereby
coordinate the cellular PN and CFTR function with the needs of
the tissue and the host [41]. For example, by focusing on the more
global regulatory circuits that control the PN responsible for tissue
function through potentially unknown endocrine or neuroendo-
crine signaling pathways, as shown recently in Caenorhabditis ele-
gans models of heat stress [23], such biologically coordinated
integration of correction pathways may achieve an acceptable
solution that will signiﬁcantly beneﬁt the patient. While we have
focused on CF, it is simply one example of a large number trans-
membrane protein folding disorders where the variant fold is not
essential for the producing cell type, yet essential for tissue and
organismal physiology [49].
While CF is an example of transmembrane protein that, when
mutated, is rapidly degraded, many mutations found in transmem-
brane proteins can challenge or even saturate the FRS and DRS of
the producing cell, thereby triggering multiple stress responses
within the cell and leading to CAT and cell death if not resolved.
Examples of CAT include mutations in diseases of myelinating cells
(including Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher
disease and Multiple Sclerosis) [50], diseases of connective tissues
(ECM) [51], diseases of the eye including retinitis pigmentosa [52],
mutations in the LDL-receptor that results in ER accumulation and
activation of the FRS [53], and Alzheimer’s disease resulting in the
generation of extracellular and potentially intracellular toxic loads
of amyloid challenging the local PBs [54,55]. All of these mutations
and diseases challenge the PN and PB in different ways as the cell
attempts to protect itself from the toxic consequences of what is a
chronic challenge. CAT diseases need to be dealt with pharmaco-
logically in a different way than CNAT diseases. Here, the challenge
may not only be to restore functionality, but to abrogate the local
toxic cellular load that triggers cell death. In principle, a corrector
that adjusted the fold would solve the problem. However, that is a
tall order for one compound – particularly when considering the
chronic nature of inherited disease and the need for continual cor-
rection in response to the different PBs as the protein migrates
through the exocytic and/or endocytic compartments, or is deliv-
ered to the extracellular space (Fig. 2). An alterative approach
would be to make modest adjustments to the PN and the PB that
mitigate the folding problem by modifying the activity and/or
composition of the FRS or DRS. While it is true that such a strategywould be unlikely to be perfectly speciﬁc, since most FRS and DRS
components have multiple clients, adjusting the PN and PB is likely
to affect the levels of poorly behaved proteins (e.g., destabilized
mutants) more than those of well behaved proteins. Furthermore,
given that each protein, each mutation, each cell and tissue, and
each local PN environment is likely to be unique, these compounds
could show surprising speciﬁcity depending on concentration, dos-
ing, and the FRS/DRS component targeted (e.g., E3 ligases are much
more speciﬁc than the proteasome).8. Treating secretory disease
A different group of misfolding diseases includes the many
proteins that are synthesized as soluble proteins in the lumen
of the ER and released by cells, particularly in tissues highly en-
gaged in protein secretion such as the liver, pancreas, and the
plasma cell. Like transmembrane proteins, these can fall into
both the CAT and CNAT categories. An understanding of the ef-
fect of each mutation will be necessary for determining whether
a disease should be treated by adjusting folding energetics using
correctors, or by adjusting the PN using proteostasis regulators
as suggested above. Known CAT/CNAT secretory diseases include,
for example, a1AT deﬁciency [56], blood disorders of coagulation
[57], congenital hyperthyroid goiter [58], procollagen disorders
[59], and multiple systematic amyloidoses including light chain
amyloid (AL) disease [60], gelsolin [61] and transthyretin (TTR)
amyloid disease [46]. Many lysosomal storage diseases could
also be considered ‘secretory’ diseases with the ﬁnal destination
being the lysosome and can be corrected by infusion of the miss-
ing soluble enzyme [62].
Gaucher’s is an archetypal example of efﬁcient removal of var-
iant protein by the PN that invariably leads to loss-of-function and
CAT. This class of disease can be corrected by pharmacologics that
serve as correctors and/or that target the PN (8). In contrast, efﬁ-
cient degradation that is observed for certain a1AT variants syn-
thesized by the liver do not directly affect the hepatocyte, yet
loss of the protein leads to CNAT in the lung due to insufﬁcient
a1AT to counter the high protease activity required for normal lung
function [56]. These could be corrected by folding stabilizers or by
altering the PB controlling the targeting to DRS. On the other hand,
as observed in congenital hyperthyroid goiter disease, and blood
and bone disorders, the Z variant of a1AT can trigger aggregation
in the ER which is normally cleared through autophagy pathways
[56]. However, when aggregation exceeds the capacity of the auto-
phagic system, it triggers severe liver disease and cancer [56]. In
this case, targeting the misfolded protein for more efﬁcient degra-
dation to prevent aggregation or boosting autophagic pathways
may be an effective ﬁrst step in mitigating disease pathology,
although the loss-of-function would be a confounding issue unless
a balance between misfolding and production of some functional
protein can also be met.
An example of a CNAT secretory disease that ‘passes’ one PB, but
fails another is AL disease. This disease results in the generation of
variant kappa or lambda chains by rare plasma cell populations
[63]. Here, the light chain variant is sufﬁciently stable for synthesis
and export. However, once secreted by the plasma cell, it is unsta-
ble in the extracellular environment in response to the different
PBs affecting folding and maintenance in extracellular environ-
ments (Fig. 2) thereby triggering the formation of amyloid in distal
tissues. For unknown reasons these variants fail to be recognized as
‘problematic’ by the ER PN. Here, it may be necessary to slightly in-
crease the stringency of the PB in the ER in order to reduce variant
trafﬁcking and to promote degradation, thereby decreasing the lev-
els found in the serum. Alternatively, it remains possible to alter
the serum environment such that the variant fold is targeted for
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amyloidosis [46] and gelsolin amyloidosis [61].
As a ﬁnal example, it is not necessary have to a folding defect to
challenge the PN, as even excessive expression of wild-type pro-
teins in response to the metabolome can trigger disease as evident
in type II diabetes [11,64–66]. Here, a high-fat diet, a lack of exer-
cise, and genetic factors strongly impact the ability of the PN to
maintain the function of b-cells in the pancreas in response to
excessive insulin demand [4,11,67]. When the rate of insulin pro-
duction exceeds the capacity of the ER-associated PN and PB to fold
the protein, not only does insulin folding fail, but the PB collapses
due to overload [17]. The collapse of proteostasis capacity in the b-
cell is exempliﬁed not only by extensive deposition of aggregates
of the peptide hormone amylin that is synthesized along with insu-
lin [68,69], but also by b-cell death, presumably resulting from sus-
tained activity of the FRS. Strikingly, global modulators of the FRS,
including the histone deacetylase inhibitors (HDACi) including 4-
PBA [70,71] and activators of sirtuins [72–75] were found to atten-
uate the FRS response and restore b-cell homeostasis. Moreover,
proteostasis regulators including the glucagon-like peptide-1
(GLP-1) receptor agonist exenatide [76] and inhibitors of dipepti-
dyl peptidase-IV that block GLP-1 degradation [77], may function
by rebalancing the PN in the b-cell by globally attenuating endog-
enous FRS pathways at the organismal level. By readjusting the FRS
using core signaling pathways, these proteostasis regulators effec-
tively preserve insulin synthesis, protect b-cells from apoptosis
and promote b-cell proliferation.
9. The next step in proteostasis disease management – learning
to reprogram the PB?
While we have speciﬁcally focused on known membrane traf-
ﬁcking misfolding diseases, cancer cells clearly reprogram the PN
to sustain proliferation [35,36]. Therapies that collapse this sup-
portive PB and trigger cell death by increasing the folding load
are currently in numerous clinical trials. Moreover, the success of
viral, bacterial, and fungal pathogens may be far more dependent
on the PN than previously anticipated given their need to exploit
the PB for rapid propagation and/or survival [78]. While the depen-
dence of the cell on the PN, and hence the position and shape of the
PB, to integrate folding energetics with function in response to diet,
stress and aging pathways is now evident, many challenges remain
to learn how to reprogram the PB for beneﬁt in the clinic.
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